Filing Details
- Accession Number:
- 0000950170-24-129709
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-21 16:04:21
- Reporting Period:
- 2024-11-20
- Accepted Time:
- 2024-11-21 16:04:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
818686 | Teva Pharmaceutical Industries Ltd | TEVA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1998173 | Christine Fox | C/O Teva Pharmaceutical Industries Ltd. 124 Dvora Hanevi'A St., Tel Aviv L3 6944020 | Evp, Head Of U.s. Commercial | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Acquisiton | 2024-11-20 | 63,492 | $0.00 | 63,492 | No | 4 | M | Direct | |
Ordinary Shares | Disposition | 2024-11-20 | 19,388 | $16.87 | 44,104 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Restricted Share Units | Disposition | 2024-11-20 | 63,492 | $0.00 | 63,492 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
190,476 | No | 4 | M | Direct |
Footnotes
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2024.
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- Restricted share units were granted on November 20, 2023, with 63,492 vested on November 20, 2024, and 63,492 vesting on each of November 20, 2025, November20, 2026 and November 20, 2027.